METHODS OF ADMINISTRATION OF NMDA RECEPTOR AGONISTS

1 . A method for treating a cognitive or neurological disease, defect or disorder comprising the step of administering rapastinel or a pharmaceutically acceptable salt, ester or metabolite thereof to a patient in need thereof, wherein rapastinel is administered for an administration period of about one to about fourteen days followed by a holiday period of at least about one to sixteen weeks wherein rapastinel is not administered.

2 . The method according to claim 1 wherein said administration period is about two days.

3 . The method according to claim 1 wherein said administration period is about three days.

4 . The method according to claim 1 wherein said administration period is about four days.

5 . The method according to claim 1 wherein said administration period is about five days.

6 . The method according to claim 1 wherein said administration period is about six days.

7 . The method according to claim 1 wherein said administration period is about seven days.

8 . The method according to claim 1 wherein said administration period is about eight days.

9 . The method according to claim 1 wherein said administration period is about nine days.

10 . The method according to claim 1 wherein said administration period is about ten days.

11 . The method according to claim 1 wherein said administration period is about eleven days.

12 . The method according to claim 1 wherein said administration period is about twelve days.

13 - 32 . (canceled)

33 . The method according to any of claim 1 wherein said cognitive disease or disorder is selected from:

deficiency in memory, intellect, learning, logic ability;

reduction in any particular individual's functioning in one or more cognitive aspects;

age-related cognitive decline;

dementia;

Alzheimer's disease;

multi-infarct dementia;

alcoholic dementia or other drug-related dementia;

dementia associated with intracranial tumors or cerebral trauma;

dementia associated with Huntington's disease or Parkinson's disease;

AIDS-related dementia;

delirium; amnestic disorder;

mental retardation;

a learning disorder including reading disorder, mathematics disorder, or a disorder of written expression;

attention-deficit/hyperactivity disorder;

schizophrenia including negative symptoms;

schizophreniform disorder;

schizoaffective disorder including of the delusional type or the depressive type;

delusional disorder;

substance-induced psychotic disorder; personality disorder of the paranoid type; personality disorder of the schizoid type;

panic disorder; phobias;

obsessive-compulsive disorder;

stress disorders;

generalized anxiety disorder;

movement disorders involving Huntington's disease;

dyskinesia associated with dopamine agonist therapy;

Parkinson's disease:

restless leg syndrome;

disorders comprising as a symptom thereof a deficiency in cognition.